Showing posts with label Prostate cancer Market Share. Show all posts
Showing posts with label Prostate cancer Market Share. Show all posts

Friday 13 September 2019

Industry Updates : Prostate cancer Market Analysis by Manufacturers, Opportunities, Challenges, Drivers, Growth, Countries, Revenue, and Forecast 2027


Market Scenario:
Prostate cancer is a slow growing cancer and affects the prostate gland of the male reproductive system. The global prostate cancer market is anticipated to grow at a stable CAGR during the forecasted period owing to the creation of antecedents for its growth.


Market Dynamics:
Drivers
Growing screening and incidence of prostate cancer coupled with the growing awareness are the prime drivers of the market. According to the American Cancer Society’s 2018 prostate cancer estimates, about 164,690 new cases of prostate cancer accounting to 29,430 deaths are likely to occur in the U.S. Prostate cancer is the second leading cause of cancer death in American men after lung cancer with approximately 1 man in 41 dying of prostate cancer or its complications.
The growth in risk factors such as genetic predisposition, aging, smoking, alcoholism, and others are feeding the market as older population, and African-American men have a greater propensity of developing it. Almost 60 % of cases of prostate cancer occur in men aged 65 or older.
The development of prostate-specific antigen (PSA) testing and development of drugs such as 5α-reductase inhibitors are other drivers of the market. The high 5-year survival rate of 99 % has ensured high expenditure to control prostate cancer. The shift of prostate cancer to the developing world is represented by the fact that it is the most common cancer in males in 85 countries, thereby assuring a large market.

Restraints
The slow growth and dormant nature of prostate cancer and confined nature which may not cause serious harm or complications hamper the market. Some prostate cancer types need minimal or no treatment, which further constrains the market. The side effects of and risks and the high cost of treatment coupled with curative treatment such as prostatectomy is another deterrent to market growth.

Segments: 
The report has been segmented by product type, end users, and regions to develop a detailed view of the global prostate cancer market.
Based on product type, the market is segmented by targeted therapies, hormone therapy therapeutic vaccines, and others.
Based on end users, the market is segmented by hospitals, clinics, and others.
Based on regions, the market is segmented by North America, Europe, Asia Pacific, Middle East and Africa.

Regional Analysis:
The Americas led by the U.S. dominates the global prostate cancer market on account of the well-developed healthcare sector, high healthcare expenditure, and excellent insurance penetration.
Europe led by Germany, France, and U.K. Accounts for the second largest market owing to well-developed healthcare infrastructure, large patient pool, and high per capita income. The Asia Pacific is expected to be the fastest growing region led by India and China owing to shift of the disease towards the developing region, huge patient population, growing income and developing economy.
The Middle East & Africa market is anticipated to account for a moderate growth due to poor economic condition, poor healthcare penetration, and social conditions. The Middle East & Africa market is expected to be dominated by Gulf economies of Saudi Arabia, UAE, Kuwait, and Qatar.

Major Vendors:
Some of the leading players in this market are OncoGenex Pharmaceuticals Inc. (US), OncBioMune Pharmaceuticals Inc. (US), Endo Pharmaceuticals Inc., Tokai Pharmaceuticals, Inc. Bayer Pharma AG (Berlin), Progenics Pharmaceuticals, Inc. (US), TOLMAR Inc. (US), and others.


You Can Get More Report Of Healthcare Industry Here !! https://sites.google.com/view/healthcaremarketreports/

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312

Monday 2 September 2019

Global Prostate Cancer Market: What it got next? Find out with the latest research available at 'The Market Reports'

Overivew
The Global Prostate Cancer Market is expected to grow with a CAGR of approximately 10.5% during the forecast period from 2017-2027. prostate cancer is a disease of the prostate gland. These glands are responsible for the production and secretion of prostate fluid as a component of semen in addition to that it also acts as a regulator of urine control in men.
International Prostate Cancer Market Business Overview:
As per a survey conducted by the American Cancer Society, about 1 in 7 men are estimated to be diagnosed with prostate cancer during their lifetime. Moreover, according to a UK based government institute namely Cancer Research Organization estimated that nearly 46,690 new cases of prostate cancer were diagnosed in 2014 with a death toll of 11,287 patients. Furthermore, there are various initiatives undertaken by key players to collaborate with government organization to spread awareness regarding the clinical symptoms of prostate cancer. Moreover, the promotion of diagnostic & screening tests for early detection such as Digital Rectal Exam (DRE), and Prostate-Specific Antigen (PSA). In addition, major players including Dendreon Corporation, Sanofi, AstraZeneca Plc, Johnson & Johnson Inc., and Astellas Pharms, Inc., are aiming to develop safe and effective therapeutic products to treat tumor.
Besides, blockbuster drugs such as Zytiga, Taxotere, Xtandi, Eligard, Xofigo, and Provenge, holding a robust position in the global prostate cancer market. Johnson & Johnson’s brand Zytiga is considered as a gold standard for the treatment of prostate cancer. Rise in the funding in both private and public sector for the drug development, technological advancements in finding new techniques to fight prostate cancer,  lifestyle changes, are few factors driving the growth of the market. Side effects of surgery such as urinary impotence & incontinence and surgical risks such as blood clots, stroke, and heart attack are certain constraints encountered by the global prostate cancer market.
Prostate Cancer Market Top Key Players Overview:
OncoGenex Pharmaceuticals Inc., Bayer Pharma AG (Germany), Progenics Pharmaceuticals, Inc. (US), TOLMAR Inc. (US), OncBioMune Pharmaceuticals Inc. (US), Endo Pharmaceuticals Inc. (US), Tokai Pharmaceuticals Inc. (US),  Active Biotech (US), ADC Therapeutics (US), Advantagene (US), Advaxis Pharmaceuticals (US), ANI Pharmaceuticals (US), ArQule (US), Athenex Pharmaceuticals (US), Bavarian Nordic (US), BHR Pharma (US), Boehringer Ingelheim (Germany), Cleveland BioLabs (US), Dextech Medical (US), Eisai (US), Endo Pharmaceuticals (US), Ferring Pharmaceutical (US), GTx (US), Innocrin Pharmaceutical (US), Inspyr Therapeutics (US), Io Therapeutics (US), Lidds AB (US), Merck Group (US), Myovant Sciences (US), Northwest Biotherapeutics (US), Novartis AG (Switerzland), Nymox Pharmaceuticals (US), OncoGenex (US), Oncolytics Biotech (US), Orion (US), CureVac (US), Pharmamar (US), Camurus (US), Foresee Pharmaceuticals (US), Progenics Pharmaceuticals (US), Sotio (US), Spectrum Pharmaceuticals (US), Synta (US), Takeda Pharmaceuticals (Japan), Teva Pharmaceutical (Israel), Tokai Pharmaceuticals (US), AbbVie (US),  Astellas Pharma (Japan), AstraZeneca (US), Johnson & Johnson (US), Sanofi (France), Ipsen (US), Valeant Pharmaceuticals (US), Dendreon Corporation (US), and others are some of the prominent players at the forefront of competition in the global prostate cancer market and are profiled in MRFR Analysis.
Industry Updates
March, 2018 Astellas pharma received FDA approval for Xtandi tablets, a treatment for castration-resistant prostate cancer, in Japan
Jan, 2015 Janssen Pharmaceutical Companies r received FDA approval for Zytiga (abiraterone acetate) for the treatment of prostate cancer
Global Prostate Cancer Market - Regional Analysis:
The global prostate cancer market is segmented into five major regions including Americas, Europe, Asia Pacific, and Middle East and Africa region.
Americas dominated the global prostate cancer market in terms of revenue share owing to the increasing R&D in the region and presence of big outsourcing firms. In the U.S., it is the most common cancer in men, but it is also treatable if found in the early stages. Prostate Cancer Foundation of Canada supports research, cure, and prevention of prostate cancer via online portal. According to the American Cancer Society in 2017 expected that about 161,360 new cases of prostate cancer will be diagnoses, and that around 26,730 fatalities will occur because of it.
The European market is the second largest market for prostate cancer plays an important role to minimize the cost of clinical trials. Furthermore, Asia Pacific region has emerged as the fastest growing market for prostate cancer.
The Middle-East and Africa prostate cancer market has been evaluated as moderately growing market and it is expected that the market will continue to grow at same pace in the near future.
Table of Contents
1 INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Thursday 30 May 2019

Prostate cancer Market Rising Healthcare Expenditure In Emerging Regions And Developed Economies!!

Prostate Cancer Market study with Detailed Review, Portraying about the Product/Industry Scope and Expounds Industry Outlook and status to 2027.

Global Prostate cancer Market – Overview
The global prostate cancer market is showing the steady growth; mainly owing to increase in patient population. According to report published by Centers for Disease Control and Prevention, in 2014, there were around 172,258 men in the United States, who diagnosed with prostate cancer and around 28,343 men died from prostate cancer. These rising number of prostate cancer create an opportunity for the player to introduce innovative treatment option.


Companies are continuously invent new treatment to capture the global market. Thus players invest more in research and development activities. In this regards, Bayer Pharma AG announced that they have many drugs for the treatment of prostate cancer in there pipeline such as Radium-223 dichloride and BAY 1841788 (ODM-201, AR antagonist).
Progenics Pharmaceuticals, Inc., 2015, acquired Exini Diagnostics AB in order to support its imaging and therapeutic agents with sophisticated analytical tools and other technologies to help patients and physicians understand, target and treat prostate cancer. These companies are more investing in research and development program to provide the best treatment option, which help them to keep ahead with their competitor.
These acquisitions help companies to provide better treatment opportunity in the market and hence improve the quality of life for the people around the world. Additionally it help market players in translating breakthrough science into innovative treatment to help people with prostate cancer worldwide.

Competitive Analysis
Some of the noteworthy players in the global prostate cancer market include Progenics Pharmaceuticals, Inc. (US), Endo Pharmaceuticals Inc. (Ireland), Bayer Pharma AG (Berlin), OncoGenex Pharmaceuticals Inc. (US), OncBioMune Pharmaceuticals Inc. (US), TOLMAR Inc. (US), and others.
January 30th, 2019, Researchers at the Medical University of South Carolina revealed the successful completion of the world’s first-ever prostate cancer surgery by using Blu Build Cesium-131 brachytherapy delivery system.
February 15th, 2019, Bayer partnering with Orion revealed the numbers showcasing the efficacy of their drug, darolutamide. The report revealed that the drug helped curb down the risk of metastasis or even death by a striking 59% in patients with non-metastatic castration-resistant prostate cancer.
Prostate Cancer Market - Segmentation
The global prostate cancer market segmentation is done on the basis of end-users and product type.
By product type, the market includes hormone therapy, targeted therapies, therapeutic vaccines, and others.
By end-users, the market segments into clinics, hospitals, and others.


Regional Analysis
The regional segmentation of the global prostate cancer market is spearheaded by North America and includes other notable regions like Europe, Asia-Pacific, and Middle East & Africa.
North Americas’ dominant standing in the market is expected to grow further during the forecast period. This can be credited primarily due to the high obesity population. This has prompted the government to be more focused on research and development activities, thereby bringing forward the best treatment facilities for the affected population.
Europe is another huge market for prostate cancer because of the huge existing population affected by this condition. Well-developed treatment facilities, the presence of major market players, and the government’s repeated effort in spreading awareness and educating the population about prostate cancer are all important drivers of the market. 
Asia-Pacific is another region expected to grow during the review period due to the presence of a huge population being affected with the condition. Highly populated countries in this region, India and China, have a huge obesity population, which can potentially lead to incidences of prostate cancer.
Plus, these countries are willing to adopt new technologies and treatment options from developed countries. This is pushing the market growth herein. The Middle East and Africa region boast the least growth potential among all the mentioned regions.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for Asia Pacific, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312